Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia

• Published in: Clinical and translational medicine 2022-09, Vol.12 (9), p.e1038-n/a
• Main Authors: Jiang, Liling, He, Qingyan, Chen, Xin, Liu, Aochu, Ding, Wa, Zhang, Haichuan, Chen, Xinmei, Zhou, Huan, Meng, Yi, Liu, Bingyuan, Peng, Guanjie, Wang, Chunyan, Liu, Jinbao, Shi, Xianping
• Format: Article
• Language: English
• Subjects: Antibodies; Apoptosis; BCR‐ABLT315I; b‐AP15; Clinical medicine; CML; Experiments; Kinases; Leukemia; Medical research; Multiple myeloma; Proteins; UCHL5; USP14
• ISSN: 2001-1326; 2001-1326
• DOI: 10.1002/ctm2.1038

Background Chronic myeloid leukaemia (CML) is a haematological cancer featured by the presence of BCR‐ABL fusion protein with abnormal tyrosine kinase activation. Classical tyrosine kinase inhibitor (TKI)‐based therapies are available to patients with CML. However, acquired resistance to TKI has been a challenging obstacle, especially stubborn T315I mutation is the most common cause. Therefore, it is especially urgent to find more effective targets to overcome TKI resistance induced by BCR‐ABLT315I. Proteasomal deubiquitinases (USP14 and UCHL5) have fundamental roles in the ubiquitin‐proteasome system and possess multiple functions during cancer progression. Methods The human peripheral blood mononuclear cells were collected to measure the mRNA expression of USP14 and UCHL5, as well as to detect the toxicity effect of b‐AP15. We explored the effect of b‐AP15 on the activity of proteasomal deubiquitinases. We detected the effects of b‐AP15 on BCR‐ABLWT and BCR‐ABLT315I CML cells in vitro and in the subcutaneous tumour model. We knocked down USP14 and/or UCHL5 by shRNA to explore whether these proteasomal deubiquitinases are required for cell proliferation of CML. Results In this study, we found that increased expression of the proteasomal deubiquitinase USP14 and UCHL5 in primary cancer cells from CML patients compared to healthy donors. b‐AP15, an inhibitor of USP14 and UCHL5, exhibited potent tumour‐killing activity in BCR‐ABLWT and BCR‐ABLT315I CML cell lines, as well as in CML xenografts and primary CML cells. Mechanically, pharmacological or genetic inhibition of USP14 and UCHL5 induced cell apoptosis and decreased the protein level of BCR‐ABL in CML cells expressing BCR‐ABLWT and BCR‐ABLT315I. Moreover, b‐AP15 synergistically enhanced the cytotoxic effect caused by TKI imatinib in BCR‐ABLWT and BCR‐ABLT315I CML cells. Conclusion Collectively, our results demonstrate targeting USP14 and UCHL5 as a potential strategy for combating TKI resistance in CML. b‐AP15, an inhibitor of proteasomal deubiquitinases USP14 and UCHL5, induces cell apoptosis and downregulates BCR‐ABL signaling in BCR‐ABLWT and BCR‐ABLT315I CML cell lines and primary CML cells. Silencing of USP14 and UCHL5 suppresses cell proliferation and decreases BCR‐ABL expression in CML cells. USP14 and UCHL5 are potential targets for combating T315I mutant‐triggered TKI resistance in CML.